

Important information

This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forward-looking statements are based on current expectations about future events. Although the expectations described in these statements are assumed to be reasonable, there is no guarantee that such forward-looking statements will materialize or are accurate. Since these statements involve assumptions and estimates that are subject to risks and uncertainties, results could differ materially from those set out in the statement. Certain of these risks and uncertainties are described further in the Annual Report in section “Risks and uncertainties”. Elekta undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or stock exchange regulations. This presentation is intended for investors and analysts only. Some products are still in research and/or not cleared/approved in all markets. Cancer statistics are given to show the potential market in the respective area and does not mean that Elekta currently has products to treat these indications

A photograph of a city skyline at dusk, featuring several tall buildings with illuminated windows and a prominent tower with a flag on top. The sky is a deep blue. A teal banner with a fine grid pattern is overlaid on the top left of the image.

Thought Leader in Precision Radiation Medicine

Dr. Richard Hausmann
President and CEO



Before we start



Radiation medicine proven to make a great difference in oligometastatic disease

3 newly published trials report survival benefit of consolidative radiation therapy

Lung cancer: Gomez et al ASTRO 2018

Prostate cancer: Parker et al ESMO 2018

All tumors: Palma et al ASTRO 2018

**A quick recap
from the Capital
Markets Day**

Message 1:

**Elekta is a better
company now**



**I see opportunity
to improve Elekta
even further**



Message 2:

**Our market is
there and strong**

An attractive growing global market



\$ ~7bn

Global radiotherapy market

~7%

Current market growth rate

Message 3:


**We have a clear
strategy forward**

We focus on...

Precision

Radiation

Medicine



Our history is what drives us forward

Elekta was founded by Lars Leksell more than 46 years ago. We have dedicated ourselves to pioneering precision radiation medicine.

Dr. Lars Leksell (1907 – 1986)
Professor of Neurosurgery



SOFTWARE SOLUTIONS


MOSAIQ
Oncology
Information System



MOSAIQ
Oncology
Analytics




METRIQ/LGK
Cancer Registries



Oncology Informatics



Plan of care



Monaco
Adaptive
planning




Image & Plan
Review

Treatment pathway Management

TREATMENT SOLUTIONS



Versa HD

Linac



Unity

MR Linac




Flexitron

Brachy



Icon

Neuro





Proton




Elekta Unity has a CE Mark but is not available for commercial distribution or sale in the U.S.

**Elekta Unity is
precision radiation
medicine by definition**




Patients are being treated as we speak

Courtesy UMC, Utrecht



Metastatic pelvic lymph node

T2w, TE 140ms, 3.5 mm sl., 1.1 x 1.1 mm res.



Metastatic axilla lymph node

3D T2w STIR, 1.5 mm sl., 1.5 x 1.5 mm res.

At multiple locations


Courtesy University of Tübingen

Treatment plan for 35 Gy in 5 fractions (Left)

Live MRI - 5 frames/s (right)

Treatment of metastatic pelvic lymph node




Pre-irradiated area (bowel, bone) with the need for maximum precision



T2w, TE 140ms, 3.5 mm sl., 1.1 x 1.1 mm res.




Our pioneers



Elekta Unity has a CE Mark but is not available for commercial distribution or sale in the U.S.

**Driving precision
radiation medicine
across our portfolio**

Driving portfolio growth



Linacs

- Unity and “halo effect”
- Introduce HD Edition
- Capture upgrade cycles

Informatics

- Drive software penetration through bundling
- New functionality and add-ons

Neurosurgery

- Capture SRS growth with LGK
- Dual focus; Neurological clinics and Oncology centers

Brachytherapy

- Re-establish specialist sales channels within Brachytherapy
- Realize emerging market potential

Introducing our new family of HD Linacs here at ASTRO



Versa HD

Push the boundaries of your stereotactic capabilities




Infinity HD

Flexibility redefined, truly multifunctional



Synergy HD

Proven technology for everyone, everywhere



Elekta Digital – guiding tomorrow's solutions

Super accurate AI based contouring will enhance confidence

Complete virtual assistant joining patients and family support systems from home to hospital and beyond

Genetic profiling means we already know how we will treat the patient... even before they are diagnosed



MOSAIQ Plaza – a strong foundation to expand our future offering





Precision radiation medicine made easy to use and more accessible

- Turnkey solutions
- Ease of installation
- Intelligent automation
- Affordability
- Supported by solid training & education

We have set ambitious targets

FY18/19 Guidance

Net Sales ~7%

EBITA ~20%

Mid Term Scenario* Until FY22/23

8-10%

Net Sales CAGR over period
(based on constant exchange rates)

EBITA >20%

with expansion of up to
200 BPS
in the end of the period

* Replaces Elekta's current long-term financial ambitions

My Promise:

Drive Elekta
into the future
as we drove it
the last two
years!



**We
will
be #1**



The logo features a stylized teal letter 'C' with three teal circles of varying sizes inside it, arranged in a diagonal line from the center towards the top right.

Eleakta